A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results.
CRISPR
blood coagulation disorders
gene editing
haemophilia
lexicon
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
revised:
01
10
2024
received:
17
06
2024
accepted:
02
10
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
22
10
2024
Statut:
aheadofprint
Résumé
Despite the progress in gene editing platforms like CRISPR/Cas9 with the potential to transform the standard of care for haemophilia, the language used to explain and discuss gene editing is not aligned across the haemophilia community. Here, we present the objective and rationale for developing a clear, consistent, and globally aligned gene editing lexicon to address these communication gaps. Effectively communicating complex gene editing concepts requires a clear and consistent vocabulary. Through collaboration with a diversity of haemophilia stakeholders, our main goal is to develop an accurate, informative lexicon which avoids overpromising or highly technical terminology. Using an innovative process, representatives from several patient and scientific haemophilia organizations and select biotechnology companies will develop and refine language concepts to be tested with approximately seventy participants across the United States of America, United Kingdom, and Germany. Participants will include lived experience experts (LEEs) and haematologists. The process will be overseen by the Lexicon Steering Committee of global experts from leading scientific and patient organizations in the haemophilia and gene editing fields. Initial feedback provided a robust foundation and rationale for building clear, consistent language around gene editing. This lexicon development framework will allow for increased understanding across the haemophilia community, including the development of valid informed consent and shared decision-making materials. Results provide important building blocks for stimuli development and highlight the need for a novel gene editing lexicon. In the next phase, language stimuli will be tested with LEEs and haematologists to better understand audience preferences and help shape the final lexicon.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Regeneron Pharmaceuticals, Inc.
Organisme : Intellia Therapeutics, Inc
Informations de copyright
© 2024 The Author(s). Haemophilia published by John Wiley & Sons Ltd.
Références
Marchesini E, Morfini M, Valentino L. Recent advances in the treatment of hemophilia: a review. Biologics. 2021;15:221‐235.
Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133(5):389‐398.
Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. J Thromb Haemost. 2023;21(3):403‐412.
Gogia P, Tarantino M, Schramm W, Aledort L. New directions to develop therapies for people with hemophilia. Expert Rev Hematol. 2023;16(6):417‐433.
Iorio A, Skinner MW, Clearfield E, et al. Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project. Haemophilia. 2018;24(4):e167‐e172.
Brod M, Bushnell DM, Neergaard JS, Waldman LT, Busk AK. Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo‐TEM). J Patient Rep Outcomes. 2023;7(1):17.
Zhang H, McCarty N. CRISPR‐Cas9 technology and its application in haematological disorders. Br J Haematol. 2016;175(2):208‐225.
De Wolf D, Singh K, Chuah MK, VandenDriessche T. Hemophilia gene therapy: the end of the beginning?. Hum Gene Ther. 2023;34(17‐18):782‐792.
Astermark J, Blatný J, Königs C, Hermans C, Jiménez‐Yuste V, Hart DP. Considerations for shared decision management in previously untreated patients with hemophilia A or B. Ther Adv Hematol. 2023;14:20406207231165857.
Pierce GF, Pasi KJ, Coffin D, et al. Towards a global multidisciplinary consensus framework on haemophilia gene therapy: report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia. 2020;26(3):443‐449.
Khair K, Steadman L, Chaplin S, Holland M, Jenner K, Fletcher S. Parental perspectives on gene therapy for children with haemophilia: the Exigency study. Haemophilia. 2021;27(1):120‐128.
Fletcher S, Jenner K, Pembroke L, Holland M, Khair K. The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study. Orphanet J Rare Dis. 2022;17(1):155.
Pietu G, Giraud N, Chamouard V, Duport G, Lienhart A, Dargaud Y. Perspectives and perception of haemophilia gene therapy by French patients. Haemophilia. 2024;30(1):68‐74.
Limjoco J, Calatroni A, Aristizabal P, Thornburg CD. Gene therapy preferences and informed decision‐making: results from a National Hemophilia Foundation Community Voices in research survey. Haemophilia. 2023;29(1):51‐60.
Limjoco J, Thornburg CD. Development of a haemophilia A gene therapy shared decision‐making tool for clinicians. Haemophilia. 2023;29(5):1184‐1190.
Hart DP, Branchford BR, Hendry S, et al. Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study. Orphanet J Rare Dis. 2021;16(1):189.
Aradom E, Gomez K. The patient gene therapy journey: findings from qualitative interviews with trial participants at one UK haemophilia centre. J Haem Pract. 2021;8(1):32‐44.
Centers for Disease Control and Prevention. Diagnosing Hemophilia. 2023. Accessed January 29, 2024. https://www.cdc.gov/hemophilia/testing/?CDC_AAref_Val